TEVA RSI Chart
Last 7 days
7.3%
Last 30 days
-4.4%
Last 90 days
15.9%
Trailing 12 Months
62.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 14.9B | 15.0B | 15.3B | 15.8B |
2022 | 15.6B | 15.4B | 15.1B | 14.9B |
2021 | 16.3B | 16.3B | 16.2B | 15.9B |
2020 | 17.1B | 16.8B | 16.7B | 16.7B |
2019 | 17.5B | 17.1B | 16.8B | 16.9B |
2018 | 21.7B | 20.5B | 19.3B | 18.3B |
2017 | 22.7B | 23.4B | 23.5B | 22.4B |
2016 | 19.5B | 19.6B | 20.3B | 21.9B |
2015 | 20.3B | 20.2B | 19.9B | 19.7B |
2014 | 20.4B | 20.5B | 20.5B | 20.3B |
2013 | 20.2B | 20.1B | 20.2B | 20.3B |
2012 | 19.2B | 20.0B | 20.6B | 20.3B |
2011 | 16.5B | 17.0B | 17.1B | 18.3B |
2010 | 16.6B | 17.0B | 17.7B | 16.1B |
2009 | 11.7B | 12.2B | 12.9B | 16.1B |
2008 | 9.8B | 10.2B | 10.7B | 11.1B |
2007 | 0 | 0 | 0 | 9.4B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 06, 2024 | kalif eliyahu sharon | sold | -1,048,120 | 13.5154 | -77,550 | evp, chief financial officer |
Mar 05, 2024 | daniell richard | acquired | - | - | 77,802 | exec. vp, european commercial |
Mar 05, 2024 | conway vikki l | acquired | - | - | 4,954 | see remarks |
Mar 05, 2024 | weiss amir | acquired | - | - | 3,564 | chief accounting officer |
Mar 05, 2024 | kalif eliyahu sharon | acquired | - | - | 73,707 | evp, chief financial officer |
Mar 05, 2024 | drape eric | acquired | - | - | 77,802 | executive vp global operations |
Mar 05, 2024 | sabag mark | sold | -1,352,090 | 13.5209 | -100,000 | evp, international markets |
Mar 05, 2024 | conway vikki l | sold | -19,286 | 13.5154 | -1,427 | see remarks |
Mar 05, 2024 | daniell richard | sold | -657,240 | 13.5154 | -48,629 | exec. vp, european commercial |
Mar 05, 2024 | sabag mark | acquired | - | - | 81,897 | evp, international markets |
Which funds bought or sold TEVA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 25, 2024 | Bank of New York Mellon Corp | reduced | -12.31 | 3,604,330 | 23,073,600 | -% |
Apr 25, 2024 | NATIXIS ADVISORS, L.P. | new | - | 2,229,000 | 2,229,000 | -% |
Apr 25, 2024 | Allworth Financial LP | added | 139 | 3,013 | 4,360 | -% |
Apr 25, 2024 | GHP Investment Advisors, Inc. | reduced | -10.00 | 4,518 | 25,398 | -% |
Apr 25, 2024 | FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | added | 1.73 | 1,417,000 | 5,197,000 | 0.06% |
Apr 25, 2024 | SIMPLEX TRADING, LLC | added | 1.64 | 2,524,000 | 9,279,000 | -% |
Apr 25, 2024 | Center for Financial Planning, Inc. | unchanged | - | 367 | 1,411 | -% |
Apr 25, 2024 | Lindbrook Capital, LLC | unchanged | - | 3,600 | 13,842 | -% |
Apr 25, 2024 | Zurcher Kantonalbank (Zurich Cantonalbank) | added | 0.53 | 1,589,010 | 6,018,490 | 0.02% |
Apr 24, 2024 | Newbridge Financial Services Group, Inc. | reduced | -88.61 | -69,777 | 12,699 | 0.01% |
Unveiling Teva Pharmaceutical Industries Ltd's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Date Filed | Form Type | Document | |
---|---|---|---|
Peers (Alternatives to Teva Pharmaceutical Industries Ltd)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 352.0B | 85.2B | 10.01 | 4.13 | ||||
MRK | 332.3B | 60.1B | 910.36 | 5.53 | ||||
AMGN | 144.7B | 28.2B | 21.54 | 5.13 | ||||
PFE | 143.3B | 46.5B | -103.22 | 3.08 | ||||
GILD | 81.5B | 27.1B | 14.4 | 3.01 | ||||
TEVA | 15.4B | 15.8B | -26.83 | 0.97 | ||||
MID-CAP | ||||||||
PRGO | 4.3B | 4.7B | -340.71 | 0.93 | ||||
ALKS | 4.1B | 1.7B | 11.6 | 2.48 | ||||
BHC | 3.2B | 8.8B | -5.38 | 0.36 | ||||
AMPH | 2.0B | 644.4M | 14.38 | 3.07 | ||||
SMALL-CAP | ||||||||
TLRY | 1.4B | 743.2M | -3.91 | 1.85 | ||||
TXMD | 21.5M | 1.3M | -2.09 | 16.47 | ||||
ACRX | 17.8M | - | -0.97 | 0.22 | ||||
AGRX | 2.7M | 19.6M | -0.19 | 0.14 | ||||
ACOR | 906.7K | 117.6M | 0 | 0.01 |
Teva Pharmaceutical Industries Ltd News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 15.8% | 4,457,000,000 | 3,850,000,000 | 3,878,000,000 | 3,661,000,000 | 3,883,500,000 | 3,595,000,000 | 3,786,000,000 | 3,661,000,000 | 4,099,500,000 | 3,887,000,000 | 3,910,000,000 | 3,982,000,000 | 4,454,000,000 | 3,978,000,000 | 3,870,000,000 | 4,357,000,000 | 4,468,000,000 | 4,093,000,000 | 4,177,000,000 | 4,149,000,000 | 4,419,000,000 |
Gross Profit | 30.5% | 2,415,500,000 | 1,851,000,000 | 1,796,000,000 | 1,582,000,000 | 1,770,000,000 | 1,669,000,000 | 1,794,000,000 | 1,740,000,000 | 2,049,500,000 | 1,794,000,000 | 1,873,000,000 | 1,878,000,000 | 2,048,000,000 | 1,852,000,000 | 1,763,000,000 | 2,063,000,000 | 1,958,000,000 | 1,830,000,000 | 1,893,000,000 | 1,856,000,000 | 1,971,000,000 |
S&GA Expenses | 6.0% | 610,500,000 | 576,000,000 | 603,000,000 | 546,000,000 | 548,500,000 | 539,000,000 | 594,000,000 | 584,000,000 | 631,500,000 | 597,000,000 | 615,000,000 | 585,000,000 | 683,000,000 | 605,000,000 | 597,000,000 | 613,000,000 | 705,500,000 | 595,000,000 | 666,000,000 | 648,000,000 | 797,000,000 |
R&D Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 60,000,000 |
EBITDA Margin | - | 0.10 | - | 0.00 | -0.01 | -0.06 | 0.01 | 0.02 | 0.11 | 0.18 | 0.20 | -0.10 | -0.11 | -0.12 | -0.13 | 0.12 | 0.08 | 0.08 | -0.13 | -0.12 | -0.08 | 0.00 |
Income Taxes | 437.5% | 40,500,000 | -12,000,000 | -16,000,000 | -19,000,000 | 149,000,000 | 107,000,000 | -900,000,000 | 2,000,000 | -24,500,000 | 76,000,000 | 98,000,000 | 62,000,000 | -21,000,000 | 16,000,000 | -104,000,000 | -59,000,000 | -119,000,000 | 11,000,000 | -179,000,000 | 9,000,000 | -139,000,000 |
Earnings Before Taxes | 665.6% | 490,000,000 | 64,000,000 | -923,000,000 | -272,000,000 | -1,185,000,000 | 171,000,000 | -1,178,000,000 | -971,000,000 | -175,500,000 | 382,000,000 | 308,000,000 | 144,000,000 | 137,000,000 | -4,459,000,000 | -51,000,000 | -33,000,000 | -39,000,000 | -292,000,000 | -850,000,000 | -84,000,000 | -3,387,000,000 |
EBT Margin | 73.3% | -0.04 | -0.15 | -0.15 | -0.16 | -0.21 | -0.14 | -0.12 | -0.03 | 0.04 | 0.06 | -0.24 | -0.26 | -0.26 | -0.27 | -0.02 | -0.07 | -0.07 | -0.27 | -0.26 | -0.22 | -0.14 |
Net Income | 536.4% | 445,500,000 | 70,000,000 | -871,000,000 | -220,000,000 | -1,301,000,000 | 61,000,000 | -251,000,000 | -955,000,000 | -159,000,000 | 292,000,000 | 207,000,000 | 77,000,000 | 150,000,000 | -4,349,000,000 | 140,000,000 | 69,000,000 | 110,000,000 | -314,000,000 | -689,000,000 | -105,000,000 | -2,886,000,000 |
Net Income Margin | 76.1% | -0.04 | -0.15 | -0.15 | -0.11 | -0.16 | -0.09 | -0.07 | -0.04 | 0.03 | 0.04 | -0.24 | -0.24 | -0.24 | -0.24 | 0.00 | -0.05 | -0.06 | -0.24 | -0.23 | -0.19 | -0.12 |
Free Cashflow | 23580.0% | 1,184,000,000 | 5,000,000 | 205,000,000 | -284,000,000 | 831,000,000 | 421,000,000 | -4,000,000 | -206,000,000 | 303,000,000 | 383,000,000 | 105,000,000 | -555,000,000 | 155,000,000 | 164,000,000 | 142,000,000 | 177,000,000 | 419,000,000 | 156,000,000 | -339,000,000 | -13,000,000 | 154,000,000 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | 3.3% | 43,479 | 42,095 | 43,100 | 43,461 | 44,011 | 44,252 | 45,932 | 47,059 | 47,666 | 47,851 | 49,195 | 49,004 | 50,640 | 49,737 | 54,991 | 55,330 | 57,470 | 57,246 | 59,424 | 59,854 | 60,683 |
Current Assets | 9.3% | 12,485 | 11,425 | 12,088 | 11,501 | 12,051 | 11,453 | 12,164 | 12,451 | 12,573 | 12,154 | 12,822 | 12,401 | 13,005 | 12,160 | 12,781 | 12,884 | 13,464 | 12,542 | 13,805 | 13,431 | 13,794 |
Cash Equivalents | 43.4% | 3,226 | 2,249 | 2,670 | 2,176 | 2,801 | 2,225 | 2,091 | 2,250 | 2,165 | 2,045 | 2,436 | 1,743 | 2,177 | 1,827 | 2,402 | 1,804 | 1,975 | 1,241 | 2,165 | 1,973 | 1,782 |
Inventory | -0.7% | 4,021 | 4,051 | 4,109 | 4,118 | 3,833 | 3,859 | 4,049 | 4,012 | 3,818 | 4,167 | 4,362 | 4,406 | 4,403 | 4,516 | 4,361 | 4,290 | 4,422 | 4,636 | 4,850 | 4,782 | 4,731 |
Net PPE | 2.3% | 5,750 | 5,622 | 5,712 | 5,751 | 5,739 | 5,568 | 5,740 | 5,932 | 5,982 | 6,040 | 6,127 | 6,112 | 6,296 | 6,152 | 6,122 | 6,221 | 6,436 | 6,643 | 6,732 | 6,785 | 6,868 |
Goodwill | 1.7% | 17,177 | 16,885 | 17,118 | 17,799 | 17,633 | 18,433 | 18,837 | 19,986 | 20,040 | 20,179 | 20,421 | 20,302 | 20,624 | 20,228 | 24,616 | 24,490 | 24,846 | 24,657 | 24,913 | 24,822 | 24,917 |
Liabilities | 1.9% | 35,353 | 34,708 | 35,508 | 34,957 | 35,413 | 34,747 | 36,121 | 36,799 | 36,422 | 36,400 | 37,884 | 38,029 | 39,579 | 39,145 | 40,167 | 40,742 | 42,407 | 42,322 | 44,173 | 44,033 | 44,889 |
Current Liabilities | 7.5% | 12,247 | 11,394 | 11,843 | 10,411 | 11,469 | 11,534 | 10,996 | 11,613 | 11,027 | 11,825 | 12,691 | 12,089 | 13,164 | 12,103 | 11,751 | 12,322 | 13,674 | 14,107 | 14,452 | 14,028 | 14,322 |
Shareholder's Equity | 1.6% | 7,506 | 7,387 | 7,592 | 8,504 | 7,804 | 9,506 | 9,810 | 10,260 | 11,244 | 11,451 | 11,311 | 10,975 | 11,061 | 10,592 | 14,824 | 14,588 | 15,063 | 14,925 | 15,251 | 15,821 | 15,794 |
Retained Earnings | 3.3% | -13,534 | -13,995 | -14,066 | -13,194 | -12,975 | -11,673 | -11,734 | -11,484 | -10,529 | -10,370 | -10,662 | -10,869 | -10,946 | -11,096 | -6,747 | -6,887 | -6,956 | -7,066 | -6,752 | -6,063 | -5,958 |
Additional Paid-In Capital | 0.1% | 27,807 | 27,780 | 27,748 | 27,719 | 27,688 | 27,652 | 27,625 | 27,587 | 27,561 | 27,529 | 27,503 | 27,474 | 27,443 | 27,403 | 27,374 | 27,342 | 27,312 | 27,293 | 27,258 | 27,234 | 27,210 |
Shares Outstanding | -0.2% | 1,119 | 1,121 | 1,120 | 1,115 | 1,110 | 1,111 | 1,110 | 1,107 | 1,102 | 1,103 | 1,101 | 1,099 | 1,095 | 1,096 | 1,096 | 1,093 | 1,091 | 1,091 | 1,091 | 1,090 | 1,021 |
Minority Interest | 6.5% | 620 | 582 | 656 | 751 | 794 | 751 | 791 | 916 | 966 | 984 | 987 | 975 | 1,035 | 999 | 972 | 1,057 | 1,091 | 1,134 | 1,128 | 1,089 | 1,087 |
Float | - | - | - | 8,380 | - | - | - | 7,300 | - | - | - | 9,550 | - | - | - | 11,830 | - | - | - | 8,820 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 23580.0% | 1,184 | 5.00 | 324 | -145 | 973 | 543 | 123 | -49.00 | 456 | 529 | 218 | -405 | 331 | 307 | 273 | 305 | 538 | 325 | -227 | 112 | 367 |
Share Based Compensation | -9.7% | 28.00 | 31.00 | 30.00 | 32.00 | 36.00 | 26.00 | 39.00 | 24.00 | 33.00 | 26.00 | 29.00 | 31.00 | 38.00 | 29.00 | 32.00 | 30.00 | 20.00 | 35.00 | 30.00 | 34.00 | 33.00 |
Cashflow From Investing | 63.6% | 301 | 184 | 302 | 181 | 169 | 147 | 179 | 161 | 246 | 288 | 481 | 508 | 141 | 157 | 313 | 252 | 430 | 224 | 429 | 272 | 74.00 |
Cashflow From Financing | 0% | -576 | -576 | -55.00 | -706 | -711 | -439 | -338 | 2.00 | -501 | -1,177 | -1.00 | -493 | -125 | -1,057 | -3.00 | -700 | -241 | -1,461 | -35.00 | -189 | -499 |
Dividend Payments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Consolidated Statements of Income (Loss) - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||||||
---|---|---|---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |||||
Net revenues | $ 15,846 | $ 14,925 | $ 15,878 | ||||
Cost of sales | 8,200 | 7,952 | 8,284 | ||||
Gross profit | 7,645 | 6,973 | 7,594 | ||||
Research and development expenses, net | 953 | 838 | 967 | ||||
Selling and marketing expenses | 2,336 | 2,265 | 2,429 | ||||
General and administrative expenses | 1,162 | 1,180 | 1,099 | ||||
Intangible assets impairments | 350 | 355 | 424 | ||||
Goodwill impairment | 700 | 2,045 | 0 | ||||
Other asset impairments, restructuring and other items | [1] | 718 | 512 | 341 | |||
Legal settlements and loss contingencies | 1,043 | 2,082 | 717 | ||||
Other income | (49) | (107) | (98) | ||||
Operating (loss) income | [1] | 433 | (2,197) | 1,716 | |||
Financial expenses – net | 1,057 | 966 | 1,058 | ||||
Income (loss) before income taxes | [1],[2] | (624) | (3,163) | 658 | |||
Income taxes (benefit) | [2] | (7) | (643) | 211 | |||
Share in (profits) losses of associated companies – net | (2) | (21) | (9) | ||||
Net income (loss) | (615) | (2,499) | 456 | ||||
Net income (loss) attributable to non-controlling interests | (56) | (53) | 39 | ||||
Net income (loss) attributable to Teva | $ (559) | $ (2,446) | $ 417 | ||||
Earnings (loss) per share attributable to ordinary shareholders: | |||||||
Basic | $ (0.5) | $ (2.2) | $ 0.38 | ||||
Diluted | $ (0.5) | $ (2.2) | $ 0.38 | ||||
Weighted average number of shares (in millions): | |||||||
Basic | 1,119 | 1,110 | 1,102 | ||||
Diluted | 1,119 | 1,110 | 1,107 | ||||
|
Consolidated Balance Sheets - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 | ||
---|---|---|---|---|
Current assets: | ||||
Cash and cash equivalents | $ 3,226 | $ 2,801 | ||
Accounts receivables, net of allowance for credit losses of $95 million and $91 million as of December 31, 2023 and December 31, 2022, respectively | 3,408 | 3,696 | ||
Inventories | 4,021 | 3,833 | ||
Prepaid expenses | 1,255 | 1,162 | ||
Other current assets | 504 | 549 | ||
Assets held for sale | 70 | 10 | ||
Total current assets | 12,485 | 12,051 | ||
Deferred income taxes | 1,812 | 1,458 | ||
Other non-current assets | 470 | 441 | ||
Property, plant and equipment, net | 5,750 | 5,739 | ||
Operating lease right-of-use assets | 397 | 419 | ||
Identifiable intangible assets, net | 5,387 | 6,270 | ||
Goodwill | [1] | 17,177 | 17,633 | |
Total assets | 43,479 | 44,011 | ||
Current liabilities: | ||||
Short-term debt | 1,672 | 2,109 | ||
Sales reserves and allowances | 3,535 | 3,750 | ||
Accounts payables | 2,602 | 1,887 | ||
Employee-related obligations | 611 | 566 | ||
Accrued expenses | 2,771 | 2,151 | ||
Other current liabilities | 1,056 | 1,005 | ||
Total current liabilities | 12,247 | 11,469 | ||
Long-term liabilities: | ||||
Deferred income taxes | 606 | 548 | ||
Other taxes and long-term liabilities | 4,019 | 3,945 | ||
Senior notes and loans | 18,161 | 19,103 | ||
Operating lease liabilities | 320 | 349 | ||
Total long-term liabilities | 23,106 | 23,944 | ||
Commitments and contingencies, see note 12 | ||||
Total liabilities | 35,353 | 35,413 | ||
Teva shareholders' equity: | ||||
Ordinary shares of NIS 0.10 par value per share; December 31, 2023 and December 31, 2022: authorized 2,495 million shares; issued 1,227 million shares and 1,217 million shares, respectively | 57 | 57 | ||
Additional paid-in capital | 27,807 | 27,688 | ||
Accumulated deficit | (13,534) | (12,975) | ||
Accumulated other comprehensive loss | (2,697) | (2,838) | ||
Treasury shares as of December 31, 2023 and December 31, 2022: 106 million ordinary shares | (4,128) | (4,128) | ||
Stockholders' equity attributable to Teva shareholders | 7,506 | 7,804 | ||
Non-controlling interests | 620 | 794 | ||
Total equity | 8,126 | 8,598 | ||
Total liabilities and equity | $ 43,479 | $ 44,011 | ||
|
 | Mr. Richard D. Francis |
---|---|
 | tevapharm.com |
 | Pharmaceuticals |
 | 34004 |